Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) EBITDA Margin (2021 - 2025)

InMed Pharmaceuticals' EBITDA Margin history spans 5 years, with the latest figure at 256.36% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 5470.0% year-over-year to 256.36%; the TTM value through Dec 2025 reached 174.33%, down 1245.0%, while the annual FY2025 figure was 159.76%, 1747.0% up from the prior year.
  • EBITDA Margin reached 256.36% in Q4 2025 per INM's latest filing, down from 162.54% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 20.43% in Q2 2023 to a low of 1615.6% in Q4 2021.
  • Average EBITDA Margin over 5 years is 460.38%, with a median of 193.24% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: surged 150844bps in 2023, then plummeted -13769bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 1615.6% in 2021, then skyrocketed by 72bps to 447.25% in 2022, then skyrocketed by 71bps to 131.49% in 2023, then crashed by -53bps to 201.65% in 2024, then fell by -27bps to 256.36% in 2025.
  • Per Business Quant, the three most recent readings for INM's EBITDA Margin are 256.36% (Q4 2025), 162.54% (Q3 2025), and 138.56% (Q2 2025).